PYC to unveil early clinical data on first-in-class gene-targeted eye drugs at ARVO

PYC Therapeutics Limited ( (AU:PYC) ) has provided an announcement.

PYC Therapeutics will showcase data from its Phase 1/2 clinical trials for two lead ophthalmology candidates, VP-001 for Retinitis Pigmentosa type 11 and PYC-001 for Autosomal Dominant Optic Atrophy, at the ARVO conference in Denver from 3 to 7 May 2026. The presentations, delivered by leading eye disease specialists, will focus on safety, tolerability and emerging efficacy signals, underlining the first-in-indication potential of these most advanced therapies for their respective rare childhood blinding conditions and reinforcing PYC’s positioning in the genetic ophthalmology space.

By putting early-stage human trial data for both programs before the ophthalmology research community, PYC is seeking to build clinical and investor confidence in its RNA delivery platform and its prospects in monogenic eye diseases. Positive perception of these data could support future trial recruitment, partnership discussions and capital-raising efforts, while also signaling progress for patients with RP11 and ADOA, who currently have no approved treatment options.

The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.84 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

More about PYC Therapeutics Limited

PYC Therapeutics Limited is a clinical-stage biotechnology company focused on precision RNA therapies for patients with genetic diseases lacking treatment options. The ASX-listed firm leverages a proprietary drug delivery platform to enhance the potency of RNA medicines, targeting monogenic indications such as childhood-onset blinding eye diseases where clinical development success rates are considered higher.

Average Trading Volume: 1,544,106

Technical Sentiment Signal: Hold

Current Market Cap: A$1.2B

See more data about PYC stock on TipRanks’ Stock Analysis page.